Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;19(9):1411-7.
doi: 10.3201/eid1909.130299.

Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA

Affiliations

Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA

Amy Parker Fiebelkorn et al. Emerg Infect Dis. 2013.

Abstract

Although the measles-mumps-rubella (MMR) vaccine is not recommended for mumps postexposure prophylaxis (PEP), data on its effectiveness are limited. During the 2009-2010 mumps outbreak in the northeastern United States, we assessed effectiveness of PEP with a third dose of MMR vaccine among contacts in Orthodox Jewish households who were given a third dose within 5 days of mumps onset in the household's index patient. We compared mumps attack rates between persons who received a third MMR dose during the first incubation period after onset in the index patient and 2-dose vaccinated persons who had not. Twenty-eight (11.7%) of 239 eligible household members received a third MMR dose as PEP. Mumps attack rates were 0% among third-dose recipients versus 5.2% among 2-dose recipients without PEP (p=0.57). Although a third MMR dose administered as PEP did not have a significant effect, it may offer some benefits in specific outbreak contexts.

Keywords: measles-mumps-rubella vaccine; mumps; postexposure prophylaxis; third-dose MMR vaccine intervention; viruses.

PubMed Disclaimer

Figures

Figure
Figure
Exclusion criteria for household members eligible to receive a dose of measles-mumps-rubella (MMR) vaccine as postexposure prophylaxis, Orange County, New York, USA, 2009–2010.

References

    1. Koskiniemi M, Donner M, Pettay O. Clinical appearance and outcome in mumps encephalitis in children. Acta Paediatr Scand. 1983;72:603–9. - PubMed
    1. Everberg G. Deafness following mumps. Acta Otolaryngol. 1957;48:397–403. - PubMed
    1. Tarkkanen J, Aho J. Unilateral deafness in children. Acta Otolaryngol. 1966;61:270–8. - PubMed
    1. Falk WA, Buchan K, Dow M, Garson JZ, Hill E, Nosal M, et al. The epidemiology of mumps in southern Alberta 1980–1982. Am J Epidemiol. 1989;130:736–49 . - PubMed
    1. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella–vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1–57 . - PubMed

Substances

LinkOut - more resources